186 related articles for article (PubMed ID: 29622863)
1. Summary and Review of the Abstracts on Philadelphia-Negative Myeloproliferative Neoplasms Presented at Haematocon 2017.
Chatterjee T; Ahuja A
Indian J Hematol Blood Transfus; 2018 Apr; 34(2):227-232. PubMed ID: 29622863
[TBL] [Abstract][Full Text] [Related]
2. Applications of Next Generation Sequencing in Haematological Disorders-Indian Status: Updates from ISHBT 2018.
Maddali M; Balasubramanian P
Indian J Hematol Blood Transfus; 2019 Jan; 35(1):17-21. PubMed ID: 30828142
[TBL] [Abstract][Full Text] [Related]
3. Summary and Review of the Abstracts on Disorders of Red Cells and Erythropoiesis Presented at Haematocon 2016-2017.
Sharma P
Indian J Hematol Blood Transfus; 2018 Jan; 34(1):8-12. PubMed ID: 29398793
[TBL] [Abstract][Full Text] [Related]
4. Association of JAK2V617F mutation with thrombosis in Indian patients with Philadelphia negative chronic myeloproliferative neoplasms.
Singh K; Sazawal S; Chhikara S; Mahapatra M; Saxena R
Indian J Pathol Microbiol; 2018; 61(3):371-374. PubMed ID: 30004057
[TBL] [Abstract][Full Text] [Related]
5. Highlights of Abstracts on Plasma Cell Dyscrasia in the Annual Conference ISHBT (Kochi).
Chatterjee T; Ahuja A
Indian J Hematol Blood Transfus; 2019 Jan; 35(1):26-31. PubMed ID: 30828144
[TBL] [Abstract][Full Text] [Related]
6. Correlation of Thrombosis and Clinicohematological Parameters with JAK2V617F Mutation in Philadelphia-Negative CMPNs: A Study from India.
Singh K; V P; Ahuja A; Somasundarum V; Mishra K; Chatterjee T
J Lab Physicians; 2022 Dec; 14(4):394-397. PubMed ID: 36531548
[No Abstract] [Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Abass Alavi: A giant in Nuclear Medicine turns 80 and is still going strong!
Høilund-Carlsen PF
Hell J Nucl Med; 2018; 21(1):85-87. PubMed ID: 29550853
[TBL] [Abstract][Full Text] [Related]
9. Increased gene expression of histone deacetylases in patients with Philadelphia-negative chronic myeloproliferative neoplasms.
Skov V; Larsen TS; Thomassen M; Riley CH; Jensen MK; Bjerrum OW; Kruse TA; Hasselbalch HC
Leuk Lymphoma; 2012 Jan; 53(1):123-9. PubMed ID: 21806350
[TBL] [Abstract][Full Text] [Related]
10. A new potential oncogenic mutation in the FERM domain of JAK2 in BCR/ABL1-negative and V617F-negative chronic myeloproliferative neoplasms revealed by a comprehensive screening of 17 tyrosine kinase coding genes.
Aranaz P; Ormazábal C; Hurtado C; Erquiaga I; Calasanz MJ; García-Delgado M; Novo FJ; Vizmanos JL
Cancer Genet Cytogenet; 2010 May; 199(1):1-8. PubMed ID: 20417861
[TBL] [Abstract][Full Text] [Related]
11. Summary and Review of the Abstracts on Hemostasis/Thrombosis Presented at Haematocon 2018, Kochi.
Sharma P
Indian J Hematol Blood Transfus; 2019 Jan; 35(1):32-36. PubMed ID: 30828145
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of Inflammation Parameters in Philadelphia Negative Chronic Myeloproliferative Neoplasia Patients.
Hacibekiroglu T; Akinci S; Basturk A; inal B; Guney T; Bakanay SM; Dilek I
Asian Pac J Cancer Prev; 2015; 16(13):5159-62. PubMed ID: 26225646
[TBL] [Abstract][Full Text] [Related]
13. [Two myeloproliferative diseases in one patient - co-occurence of clones].
Fekete S; Reichardt J; Kozma A; Kapócs K; Meggyesi N
Orv Hetil; 2022 Jul; 163(28):1123-1129. PubMed ID: 35895464
[TBL] [Abstract][Full Text] [Related]
14. A comprehensive genome-wide analysis of long non-coding RNA and mRNA expression profiles of JAK2V617F-positive classical myeloproliferative neoplasms.
Zhou J; Wu H; Guo C; Li B; Zhou LL; Liang AB; Fu JF
Bioengineered; 2021 Dec; 12(2):10564-10586. PubMed ID: 34738870
[TBL] [Abstract][Full Text] [Related]
15. Thrombin generation - a potentially useful biomarker of thrombotic risk in Philadelphia-negative myeloproliferative neoplasms.
Mihaila RG
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2017 Mar; 161(1):50-53. PubMed ID: 28145534
[TBL] [Abstract][Full Text] [Related]
16. The JAK2 46/1 haplotype does not predispose to CALR-mutated myeloproliferative neoplasms.
Soler G; Bernal-Vicente A; Antón AI; Torregrosa JM; Caparrós-Pérez E; Sánchez-Serrano I; Martínez-Pérez A; Sánchez-Vega B; Vicente V; Ferrer-Marin F
Ann Hematol; 2015 May; 94(5):789-94. PubMed ID: 25482455
[TBL] [Abstract][Full Text] [Related]
17. Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm.
Fend F; Horn T; Koch I; Vela T; Orazi A
Leuk Res; 2008 Dec; 32(12):1931-5. PubMed ID: 18555525
[TBL] [Abstract][Full Text] [Related]
18. Highlights of Abstracts on Lymphoma in the Annual Conference ISHBT Kochi 2018.
Kar R
Indian J Hematol Blood Transfus; 2019 Jan; 35(1):22-25. PubMed ID: 30828143
[TBL] [Abstract][Full Text] [Related]
19. [Atypical myeloproliferative neoplasm with a small population of Philadelphia chromosome-positive clones in the bone marrow].
Takai K; Ushiki T; Nikkuni K; Hashidate H; Shibuya H
Rinsho Ketsueki; 2011 Feb; 52(2):73-7. PubMed ID: 21403427
[TBL] [Abstract][Full Text] [Related]
20. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
